| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Patel AM et al. | Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. | 2013 | Ann. Intern. Med. | pmid:23778904 |
| Chaisson RE et al. | Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. | 1994 | Ann. Intern. Med. | pmid:7978715 |
| Goldberger M and Masur H | Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems. | 1994 | Ann. Intern. Med. | pmid:7978725 |
| Vaira D et al. | Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. | 2007 | Ann. Intern. Med. | pmid:17438314 |
| Seow J and Chew FT | Risk factors for Helicobacter pylori resistance. | 2004 | Ann. Intern. Med. | pmid:15172911 |
| De Francesco V et al. | Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. | 2006 | Ann. Intern. Med. | pmid:16418408 |
| Trivedi S et al. | Clarithromycin and digoxin toxicity. | 1998 | Ann. Intern. Med. | pmid:9518419 |
| Yang YJ et al. | Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. | 2017 | Ann. Med. | pmid:28266875 |
| Trotti LM et al. | Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. | 2015 | Ann. Neurol. | pmid:26094838 |
| Ferreri AJ et al. | High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. | 2015 | Ann. Oncol. | pmid:25935794 |
| Di Raimondo F et al. | Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? | 2007 | Ann. Oncol. | pmid:17065587 |
| Rhee CS et al. | Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. | 2000 | Ann. Otol. Rhinol. Laryngol. | pmid:10823478 |
| Heffernan CB et al. | Does Clarithromycin Cause Hearing Loss? A 12-Year Review of Clarithromycin Therapy for Nontuberculous Mycobacterial Lymphadenitis in Children. | 2018 | Ann. Otol. Rhinol. Laryngol. | pmid:30032669 |
| Clifford K et al. | Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. | 1999 | Ann. Otol. Rhinol. Laryngol. | pmid:10214783 |
| Mullin D et al. | Mycobacterium chelonae infections involving the head and neck. | 2009 | Ann. Otol. Rhinol. Laryngol. | pmid:19894399 |
| Callaghan R and Allen M | Mycobacterium malmoense infection of the knee. | 2003 | Ann. Rheum. Dis. | pmid:14583565 |
| Hiramatsu M et al. | Risk factors that affect the surgical outcome in the management of focal bronchiectasis in a developed country. | 2012 | Ann. Thorac. Surg. | pmid:22119119 |
| Fan X et al. | Lung perfusion with clarithromycin ameliorates lung function after cardiopulmonary bypass. | 2006 | Ann. Thorac. Surg. | pmid:16488691 |
| Nelson KG et al. | Results of operation in Mycobacterium avium-intracellulare lung disease. | 1998 | Ann. Thorac. Surg. | pmid:9725364 |
| Kadir IS et al. | Recurrent acute rheumatic fever: a forgotten diagnosis? | 2004 | Ann. Thorac. Surg. | pmid:15276555 |
| Bossert T et al. | Successful management of two heart transplant recipients with mycobacterial pulmonary infections. | 2005 | Ann. Thorac. Surg. | pmid:16039241 |
| Watanabe M et al. | Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. | 2006 | Ann. Thorac. Surg. | pmid:16731124 |
| Gintovt EA | [Use of clarithromycin in the treatment of atopic dermatitis complicated by staphylococcal infection]. | 2004 | Antibiot. Khimioter. | pmid:15164520 |
| Vasil'ev IuV and Zvenigorodskaia LA | [Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer]. | 2002 | Antibiot. Khimioter. | pmid:12365323 |
| Iakovlev EA et al. | [Present stage of chemotherapy and chemoprophylaxis of rickettsiosis and Q fever]. | 2011 | Antibiot. Khimioter. | pmid:22856156 |
| Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
| Evdokimova AG et al. | [New approaches to therapy of Helicobacterpylori infection (by the materials of the Maastricht Consensus-IV, Florence, 2010)]. | 2013 | Antibiot. Khimioter. | pmid:24640139 |
| Iakovlev VP et al. | [Macrolide antibiotic clarithromycin (Klabax) in treatment of community-acquired respiratory tract infections]. | 2000 | Antibiot. Khimioter. | pmid:11210297 |
| Shcherbakov PL | [Clarithromycin in eradication therapy of helicobacter infections in children]. | 2001 | Antibiot. Khimioter. | pmid:11871315 |
| Sazykin IuO et al. | [Clarithromycin and tumor chemotherapy]. | 2000 | Antibiot. Khimioter. | pmid:11210301 |
| Iutanova NS | [Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia]. | 2004 | Antibiot. Khimioter. | pmid:15344392 |
| Budanov SV and Vasil'ev AN | [Clarithromycin: specific features of antimicrobial spectrum and clinical use]. | 2004 | Antibiot. Khimioter. | pmid:15285409 |
| Guchev IA et al. | [Evaluation of clarithromycin efficacy in the treatment of community-acquired pneumonia on the basis of the Binax NOW test results (a prospective open trial)]. | 2002 | Antibiot. Khimioter. | pmid:12619516 |
| Aoki D et al. | Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. | Anticancer Res. | pmid:15816530 | |
| Ohara T et al. | Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. | 2004 Nov-Dec | Anticancer Res. | pmid:15736403 |
| Goswami S et al. | Anti-Helicobacter pylori potential of artemisinin and its derivatives. | 2012 | Antimicrob. Agents Chemother. | pmid:22687518 |
| Inderlied CB et al. | Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. | 1994 | Antimicrob. Agents Chemother. | pmid:7986017 |
| Moon JE et al. | Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. | 2006 | Antimicrob. Agents Chemother. | pmid:16723556 |
| Walzer PD et al. | Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. | 1997 | Antimicrob. Agents Chemother. | pmid:9021174 |
| Mor N et al. | Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium. | 1994 | Antimicrob. Agents Chemother. | pmid:7695255 |
| Lacassin F et al. | Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. | 1995 | Antimicrob. Agents Chemother. | pmid:7695324 |
| Kawai Y et al. | Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. | 2013 | Antimicrob. Agents Chemother. | pmid:23459497 |
| Jorgensen JH et al. | Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. | 1991 | Antimicrob. Agents Chemother. | pmid:1834012 |
| Bermudez LE et al. | Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. | 2000 | Antimicrob. Agents Chemother. | pmid:10991834 |
| Rastogi N et al. | In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. | 2000 | Antimicrob. Agents Chemother. | pmid:10991870 |
| Segreti J et al. | In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2952061 |
| Benson CA et al. | In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. | 1987 | Antimicrob. Agents Chemother. | pmid:2952063 |
| Bogdanovich T et al. | Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. | 2006 | Antimicrob. Agents Chemother. | pmid:16495248 |
| Lounis N et al. | Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. | 1995 | Antimicrob. Agents Chemother. | pmid:7793860 |
| Fattorini L et al. | In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. | 1995 | Antimicrob. Agents Chemother. | pmid:7793873 |